Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies

Abstract Background Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies. Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed this by examining the reporting of experimental conditions...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael T. C. Poon, Morgan Bruce, Joanne E. Simpson, Cathal J. Hannan, Paul M. Brennan
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	High grade glioma Glioblastoma Temodal Cell culture GBM Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/da02e9ee3efb494ea3436c9175d4c261
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da02e9ee3efb494ea3436c9175d4c261
record_format	dspace
spelling	oai:doaj.org-article:da02e9ee3efb494ea3436c9175d4c2612021-11-21T12:30:28ZTemozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies10.1186/s12885-021-08972-51471-2407https://doaj.org/article/da02e9ee3efb494ea3436c9175d4c2612021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08972-5https://doaj.org/toc/1471-2407Abstract Background Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies. Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed this by examining the reporting of experimental conditions and sensitivity to temozolomide in glioma cells lines. Methods We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line. Key data items included type of cell lines, temozolomide exposure duration in hours (hr), and cell viability measure (IC50). Results We included 212 studies from 2789 non-duplicate records that reported 248 distinct cell lines. The commonest cell line was U87 (60.4%). Only 10.4% studies used a patient-derived cell line. The proportion of studies not reporting each experimental condition ranged from 8.0–27.4%, including base medium (8.0%), serum supplementation (9.9%) and number of replicates (27.4%). In studies reporting IC50, the median value for U87 at 24 h, 48 h and 72 h was 123.9 μM (IQR 75.3–277.7 μM), 223.1 μM (IQR 92.0–590.1 μM) and 230.0 μM (IQR 34.1–650.0 μM), respectively. The median IC50 at 72 h for patient-derived cell lines was 220 μM (IQR 81.1–800.0 μM). Conclusion Temozolomide sensitivity reported in comparable studies was not consistent between or within malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies.Michael T. C. PoonMorgan BruceJoanne E. SimpsonCathal J. HannanPaul M. BrennanBMCarticleHigh grade gliomaGlioblastomaTemodalCell cultureGBMNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	High grade glioma Glioblastoma Temodal Cell culture GBM Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	High grade glioma Glioblastoma Temodal Cell culture GBM Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Michael T. C. Poon Morgan Bruce Joanne E. Simpson Cathal J. Hannan Paul M. Brennan Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
description	Abstract Background Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies. Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed this by examining the reporting of experimental conditions and sensitivity to temozolomide in glioma cells lines. Methods We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line. Key data items included type of cell lines, temozolomide exposure duration in hours (hr), and cell viability measure (IC50). Results We included 212 studies from 2789 non-duplicate records that reported 248 distinct cell lines. The commonest cell line was U87 (60.4%). Only 10.4% studies used a patient-derived cell line. The proportion of studies not reporting each experimental condition ranged from 8.0–27.4%, including base medium (8.0%), serum supplementation (9.9%) and number of replicates (27.4%). In studies reporting IC50, the median value for U87 at 24 h, 48 h and 72 h was 123.9 μM (IQR 75.3–277.7 μM), 223.1 μM (IQR 92.0–590.1 μM) and 230.0 μM (IQR 34.1–650.0 μM), respectively. The median IC50 at 72 h for patient-derived cell lines was 220 μM (IQR 81.1–800.0 μM). Conclusion Temozolomide sensitivity reported in comparable studies was not consistent between or within malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies.
format	article
author	Michael T. C. Poon Morgan Bruce Joanne E. Simpson Cathal J. Hannan Paul M. Brennan
author_facet	Michael T. C. Poon Morgan Bruce Joanne E. Simpson Cathal J. Hannan Paul M. Brennan
author_sort	Michael T. C. Poon
title	Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
title_short	Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
title_full	Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
title_fullStr	Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
title_full_unstemmed	Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
title_sort	temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
publisher	BMC
publishDate	2021
url	https://doaj.org/article/da02e9ee3efb494ea3436c9175d4c261
work_keys_str_mv	AT michaeltcpoon temozolomidesensitivityofmalignantgliomacelllinesasystematicreviewassessingconsistenciesbetweeninvitrostudies AT morganbruce temozolomidesensitivityofmalignantgliomacelllinesasystematicreviewassessingconsistenciesbetweeninvitrostudies AT joanneesimpson temozolomidesensitivityofmalignantgliomacelllinesasystematicreviewassessingconsistenciesbetweeninvitrostudies AT cathaljhannan temozolomidesensitivityofmalignantgliomacelllinesasystematicreviewassessingconsistenciesbetweeninvitrostudies AT paulmbrennan temozolomidesensitivityofmalignantgliomacelllinesasystematicreviewassessingconsistenciesbetweeninvitrostudies
_version_	1718418974824202240

Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies

Ejemplares similares